CXCR2 antagonists are also being evaluated in combination with immune checkpoint inhibitor pembrolizumab in advanced solid tumors (NCT03473925) and in metastatic melanoma (NCT03161431, not yet recruiting) (ClinicalTrials.org). Here, CXCR2 is linked to metastatic melanoma.